Anti-reflux mucosal ablation (ARMA) as a novel minimally invasive treatment for severe gastroesophageal reflux disease in a child: the first pediatric case report - Takeaways - MDSpire

Anti-reflux mucosal ablation (ARMA) as a novel minimally invasive treatment for severe gastroesophageal reflux disease in a child: the first pediatric case report

  • By

  • Jonas Povilavičius

  • Geistė Tubutytė

  • Kamilė Bagdonaitė

  • Audrius Dulskas

  • Arūnas Strumila

  • Austėja Račytė

  • June 1, 2026

  • 0 min

Share

  • 1

    ARMA is a novel, minimally invasive endoscopic technique for treating refractory gastroesophageal reflux disease in pediatric patients.

  • 2

    A 9-year-old boy with spastic cerebral palsy underwent ARMA due to severe GERD unresponsive to proton pump inhibitors.

  • 3

    The ARMA procedure was performed without complications, resulting in improved reflux control and reduced need for acid-suppressive therapy.

  • 4

    Follow-up showed significant improvement in the gastroesophageal flap valve and a marked reduction in GERD symptoms.

  • 5

    This case suggests ARMA may be a viable option for other high-risk pediatric patients with medication-resistant GERD.

Original Source(s)

Anti-reflux mucosal ablation (ARMA) as a novel minimally invasive treatment for severe gastroesophageal reflux disease in a child: the first pediatric case report

  • by Jonas Povilavičius, Geistė Tubutytė, Kamilė Bagdonaitė, Audrius Dulskas, Arūnas Strumila, Austėja Račytė

  • June 1, 2026

Related Content

PARylation-centric crosstalk: orchestrating immune evasion and multidrug resistance in ovarian cancer

Incidence of Clostridium difficile infection and enteric pathogens in children with inflammatory bowel disease presenting with disease exacerbation

Context-dependent functions of ALKBH5: a mechanistic framework linking cellular stress responses, immune regulation, viral infection, and therapeutic vulnerabilities